If you are an ARRS-funded clinical pharmacist working in a PCN, your daily work spans structured medication reviews, prescribing safety interventions, long-term condition management, and medicines optimisation — often across multiple GP practices with different systems, different formularies, and different clinical cultures. The DES contract for 2025/26 expanded the SMR priority cohorts to include patients taking antidepressants, adding to the existing high-risk groups: people diagnosed with frailty or living in care homes, those with complex polypharmacy, patients taking medicines commonly associated with medication errors, and anyone using potentially addictive pain management medicines.
NHS England's medicines optimisation guidance estimates that pharmacist-led SMRs can generate direct medicines cost savings of £13,100 per 100 reviews, rising to £168,800 per 100 reviews when avoided healthcare resource use is factored in. But delivering this value requires clinical confidence, guideline fluency, and efficient decision support tools.
This guide covers the scenarios you face daily and the toolkit that makes them manageable.
Structured Medication Reviews: What Good Looks Like
An SMR is not a medication list check. It is a person-centred, holistic review that considers the patient's clinical conditions, their medicines (prescribed, OTC, and complementary), their functional status, their goals and preferences, and the evidence base for each treatment decision.
The NICE-aligned framework for every SMR follows a consistent structure. First, establish the clinical context: diagnoses, current symptoms, functional status, frailty score (using the electronic Frailty Index if available). Second, review each medicine against four criteria: is it still indicated? Is it effective for this patient? Is it safe (interactions, renal function, anticholinergic burden)? Does the patient want to continue it? Third, identify medicines optimisation opportunities: deprescribing candidates, dose adjustments, therapeutic switches, adherence support needs. Fourth, agree actions with the patient using shared decision-making principles.
Where Ask iatroX fits: During an SMR, clinical questions arise constantly — "Is this statin dose appropriate given the patient's eGFR of 34?" / "What is the NICE recommendation for antidepressant discontinuation?" / "Does amlodipine interact with this patient's simvastatin?" Ask iatroX answers these in seconds with NICE/BNF-cited responses, eliminating the time spent navigating MedicinesComplete or searching CKS manually.
Polypharmacy Management: The STOPP/START Approach
Patients with 10+ medicines are the core of your SMR caseload. The STOPP/START criteria provide a structured framework for identifying potentially inappropriate prescribing (STOPP — Screening Tool of Older Persons' Prescriptions) and potentially beneficial medicines that are missing (START — Screening Tool to Alert to Right Treatment).
Common STOPP interventions in primary care include stopping long-term PPIs without clear indication (NICE NG184), stopping benzodiazepines prescribed long-term for insomnia (risk of falls, cognitive impairment), stopping anticholinergic drugs where the anticholinergic burden score is high (cognitive decline risk), and adjusting or stopping NSAIDs in patients with CKD stage 3+ or concurrent ACEi/ARB + diuretic ("triple whammy" nephrotoxicity risk).
Common START interventions include starting a statin where QRISK3 exceeds 10% (NICE CG181), starting an ACEi/ARB in heart failure with reduced ejection fraction, starting VTE prophylaxis where Padua score indicates moderate-high risk, and starting bone protection in patients on long-term corticosteroids.
Where iatroX Calculators fits: QRISK3 for CVD risk assessment, CKD-EPI for renal function staging, CHA₂DS₂-VASc for AF anticoagulation decisions, FIB-4 for NAFLD fibrosis screening — all with NICE-referenced interpretation.
Prescribing Safety: The Daily Interventions
As a prescribing pharmacist (or as a clinical pharmacist reviewing prescribing decisions), your prescribing safety interventions follow predictable patterns.
Renal dose adjustments. Check eGFR for every patient on renally excreted drugs. Common drugs requiring adjustment: metformin (stop or reduce if eGFR <30), DOACs (each has different renal thresholds), gabapentin/pregabalin, digoxin, lithium. Use CKD-EPI on iatroX for eGFR calculation and Cockcroft-Gault for CrCl where BNF specifies this for dosing.
Drug interactions. The interactions you catch most frequently: warfarin + macrolide antibiotics (INR increase), methotrexate + trimethoprim (pancytopenia risk), lithium + NSAIDs or ACEi (lithium toxicity), simvastatin + amlodipine at high statin dose (myopathy risk), clopidogrel + PPI (reduced antiplatelet effect — omeprazole specifically).
High-risk medicines monitoring. Methotrexate (FBC, LFTs, renal function), lithium (serum levels, thyroid, renal), DMARDs (FBC, LFTs), amiodarone (thyroid function, LFTs), DOACs (renal function annually).
Where Ask iatroX fits: Instant interaction checking and monitoring requirement verification — "What monitoring does NICE recommend for amiodarone?" / "Is co-prescribing clopidogrel and lansoprazole safer than omeprazole?" — cited, with BNF references.
The Toolkit
Your daily toolkit as a PCN clinical pharmacist should include: BNF app (formulary lookups), Ask iatroX (clinical questions with NICE/BNF-cited answers), iatroX Calculators (clinical scores with UK-contextualised interpretation), MedicinesComplete (complex interaction and excipient queries where available), and your practice's clinical system searches (Ardens or equivalent for identifying SMR-eligible patients).
For CPD and ongoing knowledge maintenance, the iatroX Q-Bank provides adaptive testing across all therapeutic areas — keeping your clinical knowledge sharp through active retrieval practice rather than passive guideline reading.